[go: up one dir, main page]

MD4685B1 - Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 - Google Patents

Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 Download PDF

Info

Publication number
MD4685B1
MD4685B1 MDA20180042A MD20180042A MD4685B1 MD 4685 B1 MD4685 B1 MD 4685B1 MD A20180042 A MDA20180042 A MD A20180042A MD 20180042 A MD20180042 A MD 20180042A MD 4685 B1 MD4685 B1 MD 4685B1
Authority
MD
Moldova
Prior art keywords
masp
complement activation
treatment
conditions associated
activation dependent
Prior art date
Application number
MDA20180042A
Other languages
English (en)
Russian (ru)
Other versions
MD4685C1 (ro
MD20180042A2 (ro
Inventor
Грегори А. ДЕМОПУЛОС
Томас Дадлер
Ганс-Вильгельм ШВАБЛЕ
Original Assignee
Omeros Corporation
University Of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation, University Of Leicester filed Critical Omeros Corporation
Publication of MD20180042A2 publication Critical patent/MD20180042A2/ro
Publication of MD4685B1 publication Critical patent/MD4685B1/ro
Publication of MD4685C1 publication Critical patent/MD4685C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Power Steering Mechanism (AREA)
  • Exhaust Gas After Treatment (AREA)

Abstract

Invenţia se referă la metode de inhibare a efectelor activării complementului dependente de MASP-2 la un subiect uman, care suferă de microangiopatie trombotică (TMA) asociată cu transplantul de celule stem hematopoietice. Metodele includ etapa de administrare la subiectul, care are nevoie de aceasta, a unei cantităţi de agent inhibitor al MASP-2, care inhibă eficient activarea complementului dependentă de MASP-2.Secvenţe: 71
MDA20180042A 2015-11-09 2016-11-09 Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 MD4685C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252814P 2015-11-09 2015-11-09
US201662406726P 2016-10-11 2016-10-11
PCT/US2016/061113 WO2017083371A1 (en) 2015-11-09 2016-11-09 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (3)

Publication Number Publication Date
MD20180042A2 MD20180042A2 (ro) 2018-09-30
MD4685B1 true MD4685B1 (ro) 2020-03-31
MD4685C1 MD4685C1 (ro) 2020-12-31

Family

ID=58691444

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20180042A MD4685C1 (ro) 2015-11-09 2016-11-09 Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2

Country Status (19)

Country Link
US (3) US20170137537A1 (ro)
EP (1) EP3373963A4 (ro)
JP (2) JP6814802B2 (ro)
KR (2) KR102277166B1 (ro)
CN (2) CN117398458A (ro)
AU (2) AU2016354117B2 (ro)
CA (1) CA3004753C (ro)
CL (1) CL2018001258A1 (ro)
EA (1) EA201891132A1 (ro)
GE (3) GEAP202314803A (ro)
IL (2) IL295200B2 (ro)
MD (1) MD4685C1 (ro)
MX (2) MX2018005165A (ro)
MY (1) MY197758A (ro)
NZ (1) NZ742987A (ro)
PH (1) PH12018501009A1 (ro)
SG (2) SG10202011469UA (ro)
UA (1) UA124094C2 (ro)
WO (1) WO2017083371A1 (ro)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3287142B1 (en) 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
CN105683219B (zh) 2013-10-17 2020-07-14 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
AU2017293767B2 (en) * 2016-07-06 2021-12-16 Microoptx Inc. Glaucoma treatment devices and methods
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TW202529812A (zh) * 2017-08-15 2025-08-01 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
AU2018322032B2 (en) * 2017-08-25 2025-04-17 Omeros Corporation Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome
SG11202010925UA (en) 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
EA202190106A1 (ru) * 2018-06-22 2021-04-13 Омерос Корпорейшн Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств
IL293363A (en) * 2019-11-26 2022-07-01 Omeros Corp Masp-2 inhibitors for use in treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
AU2020396565C1 (en) 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
KR20220110529A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
GEAP202516705A (en) 2021-12-10 2025-04-10 Omeros Corp Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
WO2025153000A1 (zh) * 2024-01-17 2025-07-24 信立泰(成都)生物技术有限公司 一种抗masp2抗体或其抗原结合片段及用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
EP1797869A3 (en) 1999-07-21 2008-07-23 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
CA2380979A1 (en) * 1999-08-13 2001-02-22 Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
EP3287142B1 (en) * 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
RS60541B1 (sr) 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
JP6445972B2 (ja) * 2012-06-18 2018-12-26 オメロス コーポレーション 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
WO2015039126A1 (en) * 2013-09-16 2015-03-19 Children hospital medical center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
CN105683219B (zh) * 2013-10-17 2020-07-14 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
KR102011118B1 (ko) * 2018-04-13 2019-08-14 김정범 개선된 스냅 단추

Also Published As

Publication number Publication date
MD4685C1 (ro) 2020-12-31
US20210047433A1 (en) 2021-02-18
GEP20247583B (en) 2024-01-10
NZ742987A (en) 2019-12-20
AU2016354117A1 (en) 2018-05-10
IL295200B1 (en) 2024-12-01
SG10202011469UA (en) 2020-12-30
CN108472347B (zh) 2023-09-05
CN117398458A (zh) 2024-01-16
CN108472347A (zh) 2018-08-31
KR20210090283A (ko) 2021-07-19
JP6814802B2 (ja) 2021-01-20
CA3004753A1 (en) 2017-05-18
MX2018005165A (es) 2020-11-11
PH12018501009A1 (en) 2019-01-28
EP3373963A4 (en) 2019-07-10
UA124094C2 (uk) 2021-07-21
IL259225B (en) 2022-09-01
IL295200B2 (en) 2025-04-01
US20170137537A1 (en) 2017-05-18
AU2016354117B2 (en) 2019-11-28
GEAP202314803A (en) 2023-06-26
BR112018009311A8 (pt) 2019-02-26
US20240343830A1 (en) 2024-10-17
MD20180042A2 (ro) 2018-09-30
IL295200A (en) 2022-10-01
BR112018009311A2 (pt) 2018-11-06
GEP20237574B (en) 2023-12-25
JP2018533592A (ja) 2018-11-15
KR102432062B1 (ko) 2022-08-12
KR20180074789A (ko) 2018-07-03
MY197758A (en) 2023-07-13
CL2018001258A1 (es) 2018-10-12
JP2021063093A (ja) 2021-04-22
KR102277166B1 (ko) 2021-07-15
US11981749B2 (en) 2024-05-14
EP3373963A1 (en) 2018-09-19
EA201891132A1 (ru) 2018-10-31
JP7629300B2 (ja) 2025-02-13
MX2023001193A (es) 2023-08-11
WO2017083371A1 (en) 2017-05-18
SG11201803834UA (en) 2018-06-28
CA3004753C (en) 2023-02-28
AU2020201500A1 (en) 2020-03-19
IL259225A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
ZA202407503B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
JOP20200291A1 (ar) معدلات التعبير عن apol1
NZ755501A (en) Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
WO2017042196A3 (en) Agents and methods using thereof for the prevention and treatment of stem cells senescence
EA201991135A1 (ru) Комбинированная терапия ингибиторами аргиназы

Legal Events

Date Code Title Description
FG4A Patent for invention issued